A Phase 2 interventional study of Abiraterone acetate and Prednisone in Prostatic Neoplasms and Prostate Cancer, sponsored by Cougar Biotechnology, Inc.. Completed at 14 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-02.
Sponsored by Cougar Biotechnology, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.
Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 46th largest by enrollment, is one of 4 that started in 2007, is one of 59 in phase 2, and was the 4th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+ · Men only
Deventer Ziekenhuis · Sites in Netherlands
Ages 18+ · Men only
By country, each count listing its studies:
Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 67 · Phase 3 11 · Phase 4 4
First in 2005; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is close to the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 56 across the 98 interventional studies. Of the 60 that completed or were terminated, 40 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Cougar Biotechnology, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Cougar Biotechnology, Inc. is the lead sponsor of 12 studies on the registry; none are open to participants now.
88 studies in Prostatic Neoplasms by Johnson & Johnson: 9 open now, 23 under way, 9 of them phase 3. Of 58 finished, 24 (41%) have results posted.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 40th largest by enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2007, is one of 20 in phase 2, and was the 8th registered.
Johnson & Johnson’s Prostatic Neoplasms studies by the year they started, since 1995.
8 of the studies testing Abiraterone Acetate in Prostatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
| NCT03902951Jonsson Comprehensive Cancer CenterAntiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | 2027-01-01 |
| NCT01786265M.D. Anderson Cancer CenterFinite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer | 2027-02-01 |
| NCT04194554University of Michigan Rogel Cancer CenterA Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, from their registry updates:
Among Johnson & Johnson’s 88 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of abiraterone acetate in participants with advanced prostate cancer (a disease in which cells in the prostate gland become abnormal and start to grow uncontrollably, forming tumors).
This is an open-label (all people know the identity of the intervention), single-arm, multicenter (when more than one hospital or medical school team work on a medical research study) study to evaluate the anti-tumor activities and safety of abiraterone acetate in participants with prostate cancer who have failed androgen deprivation and docetaxel-based chemotherapy. Abiraterone acetate oral tablet will be administered as a total dose of 1000 milligram (mg) orally (by mouth) once daily after an overnight fast and prednisone/prednisolone will be administered as 5 mg oral tablet twice daily. Participants will be enrolled and treated up to 12 cycles (or longer, if they have not progressed and continue to benefit from treatment). The study will consist of 3 parts: Screening (14 days), Open-label Treatment; and follow-up (up to 60 months). Participants will be evaluated primarily for prostate specific antigen response according to Prostate Specific Antigen Working Group (PSAWG) criteria. Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Abiraterone acetate 1000 milligram (mg) (4 oral tablets of 250 mg each) will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-days dosing cycle and will be continued until disease progression or unacceptable toxicity.
Drug: Abiraterone acetate · Drug: Prednisone
Abiraterone acetate oral tablets 250 milligram (mg) each will be administered at a total dose of 1000 mg until documented disease progression or unacceptable toxicity.
Prednisone/Prednisolone 5 mg tablet will be taken orally twice daily.
Also known as: CB7630
Percentage of Participants With Prostate Specific Antigen (PSA) Response
The PSA response was evaluated according to Prostate-Specific Antigen Working Group (PSAWG) criterion, which is, greater than or equal to 50 percent decrease in PSA from Baseline during the study, which would be subsequently confirmed by a measurement that is at least 4 or more weeks after initial documentation of PSA response.
Time frame: Day 1 of each cycle (of 28 days each) up to Cycle 12
Prostate-Specific Antigen Based Progression-free Survival (PSA-PFS)
The PSA-PFS is defined as time to first PSA failure (that is, two consecutive increases in PSA of 50 percent and greater than or equal to 5 nanogram per milliliter, as per Prostate-Specific Antigen Working Group \[PSAWG\] criterion) or death or the start of secondary anti-tumor therapy, whichever occurs first. If a PSA progression or death does not occur, subject will be censored at the last PSA evaluation.
Time frame: Baseline and Day 1 of each cycle until first documented disease progression or up to 60 months
Radiographic Progression Free Survival (PFS)
The RAD-PFS is defined as the time from randomization to the earliest objective evidence of radiographic progression or death due to any cause. Progression is defined using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0, as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Baseline, Day 1 of Cycle 4, 7 and 10, and thereafter every third cycle until first documented disease progression or up to 60 months
Overall Survival (OS)
Overall survival is defined as the interval from the date of the first dose of abiraterone acetate to the date of death.
Time frame: Every 3 months until death or up to 60 months
Percentage of Participants With Objective Radiographic Response
Percentage of participants with radiographic objective response is defined as the percentage of participants with complete response (CR) or partial response (PR) as best overall response based on reconciled radiographic disease assessment according to RECIST Version 1.0. The CR is disappearance of all lesions. The PR is at least 30 percent decrease in sum of the longest diameter of target lesions or persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.
Time frame: Baseline, Day 1 of Cycle 4, 7 and 10, and thereafter every third cycle until first documented disease progression or up to 60 months
Time to PSA Progression
The time interval from first dose of abiraterone acetate to the date of PSA progression as defined by the Prostate-Specific Antigen Working Group (PSAWG) criteria. If a PSA progression does not occur, subject will be censored at the last PSA evaluation.
Time frame: Day 8 of Cycle 1, thereafter Day 1 of each cycle up to end of study (60 months)
Time to Radiographic Progression
Time to radiographic progression is defined as the time from first dose until the first radiographic progression date that was confirmed.
Time frame: Baseline, Day 1 of Cycle 4, 7 and 10, and thereafter every third cycle until first documented disease progression or up to 60 months
Shift From Baseline in Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score
ECOG performance status score ranges from 0 to 5 where 0=fully active, perform all pre-disease activities without restriction. 1=restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature, 2=ambulatory, capable of self-care, unable to carry out any work activities, up and about more than (\>) 50 percent of waking hours, 3=capable of limited self-care, confined to bed or chair \>50 percent of waking hours, 4=completely disabled, not capable of any self-care, totally confined to bed or chair and 5=dead.
Time frame: Baseline and Day 1 of each cycle until first documented disease progression or up to 60 months
Percentage of Participants With Clinical Benefit
Clinical benefit was defined as an observation of at least 1 of the following: PSA response by PSAWG criteria; radiographic response by RECIST criteria; stable disease by RECIST criteria lasting 6 months; or improvement by at least 1 unit in ECOG performance status.
Time frame: Baseline, Day 1 of Cycle 4, 7 and 10, and thereafter every third cycle until first documented disease progression or up to 60 months
| Milestone | Abiraterone |
|---|---|
| Started | 58 |
| Completed | 2 |
| Not completed | 56 |
| Withdrew: Adverse event | 5 |
| Withdrew: Progressive disease | 44 |
| Withdrew: Other | 3 |
| Withdrew: Initiation of new anti-cancer treatment | 2 |
| Withdrew: Treatment ongoing at cutoff date | 2 |
The PSA response was evaluated according to Prostate-Specific Antigen Working Group (PSAWG) criterion, which is, greater than or equal to 50 percent decrease in PSA from Baseline during the study, which would be subsequently confirmed by a measurement that is at least 4 or more weeks after initial documentation of PSA response.
| percentage of participants | Abiraterone |
|---|---|
| Percentage of Participants With Prostate Specific Antigen (PSA) Response | 37.9 (25.5 to 51.6) |
The PSA-PFS is defined as time to first PSA failure (that is, two consecutive increases in PSA of 50 percent and greater than or equal to 5 nanogram per milliliter, as per Prostate-Specific Antigen Working Group \[PSAWG\] criterion) or death or the start of secondary anti-tumor therapy, whichever occurs first. If a PSA progression or death does not occur, subject will be censored at the last PSA evaluation.
| days | Abiraterone |
|---|---|
| Prostate-Specific Antigen Based Progression-free Survival (PSA-PFS) | 141 (110 to 200) |
The RAD-PFS is defined as the time from randomization to the earliest objective evidence of radiographic progression or death due to any cause. Progression is defined using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0, as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.
| days | Abiraterone |
|---|---|
| Radiographic Progression Free Survival (PFS) | 126 (82 to 333) |
Overall survival is defined as the interval from the date of the first dose of abiraterone acetate to the date of death.
| days | Abiraterone |
|---|---|
| Overall Survival (OS) | 492 (373 to 647) |
Percentage of participants with radiographic objective response is defined as the percentage of participants with complete response (CR) or partial response (PR) as best overall response based on reconciled radiographic disease assessment according to RECIST Version 1.0. The CR is disappearance of all lesions. The PR is at least 30 percent decrease in sum of the longest diameter of target lesions or persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.
| percentage of participants | Abiraterone |
|---|---|
| Complete response (CR) | 0 |
| Partial Response (PR) | 6.3 |
The time interval from first dose of abiraterone acetate to the date of PSA progression as defined by the Prostate-Specific Antigen Working Group (PSAWG) criteria. If a PSA progression does not occur, subject will be censored at the last PSA evaluation.
| days | Abiraterone |
|---|---|
| Time to PSA Progression | 169 (99 to 225) |
Time to radiographic progression is defined as the time from first dose until the first radiographic progression date that was confirmed.
| days | Abiraterone |
|---|---|
| Time to Radiographic Progression | 88 (82 to 333) |
ECOG performance status score ranges from 0 to 5 where 0=fully active, perform all pre-disease activities without restriction. 1=restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature, 2=ambulatory, capable of self-care, unable to carry out any work activities, up and about more than (\>) 50 percent of waking hours, 3=capable of limited self-care, confined to bed or chair \>50 percent of waking hours, 4=completely disabled, not capable of any self-care, totally confined to bed or chair and 5=dead.
| participants | Abiraterone |
|---|---|
| Baseline:0; Best Post-dose:0 | 22 |
| Baseline:0; Best Post-dose:1 | 2 |
| Baseline:0; Best Post-dose:2 | 0 |
| Baseline:0; Best Post-dose:3 | 0 |
| Baseline:0; Best Post-dose:4 | 0 |
| Baseline:1; Best Post-dose:0 | 14 |
| Baseline:1; Best Post-dose:1 | 15 |
| Baseline:1; Best Post-dose:2 | 2 |
| Baseline:1; Best Post-dose:3 | 0 |
| Baseline:1; Best Post-dose:4 | 0 |
| Baseline:2; Best Post-dose:0 | 1 |
| Baseline:2; Best Post-dose:1 | 1 |
| Baseline:2; Best Post-dose:2 | 0 |
| Baseline:2; Best Post-dose:3 | 0 |
| Baseline:2; Best Post-dose:4 | 0 |
| Baseline:0; Worst Post-dose:0 | 6 |
| Baseline:0; Worst Post-dose:1 | 17 |
| Baseline:0; Worst Post-dose:2 | 1 |
| Baseline:0; Worst Post-dose:3 | 0 |
| Baseline:0; Worst Post-dose:4 | 0 |
| Baseline:1; Worst Post-dose:0 | 0 |
| Baseline:1; Worst Post-dose:1 | 24 |
| Baseline:1; Worst Post-dose:2 | 6 |
| Baseline:1; Worst Post-dose:3 | 1 |
| Baseline:1; Worst Post-dose:4 | 0 |
| Baseline:2; Worst Post-dose:0 | 0 |
| Baseline:2; Worst Post-dose:1 | 0 |
| Baseline:2; Worst Post-dose:2 | 2 |
| Baseline:2; Worst Post-dose:3 | 0 |
| Baseline:2; Worst Post-dose:4 | 0 |
Clinical benefit was defined as an observation of at least 1 of the following: PSA response by PSAWG criteria; radiographic response by RECIST criteria; stable disease by RECIST criteria lasting 6 months; or improvement by at least 1 unit in ECOG performance status.
| percentage of participants | Abiraterone |
|---|---|
| Disease Stabilization | 12 |
| Change in participant ECOG score | 16 |
Collected over Day 8 of Cycle 1 up to End of Study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abiraterone | — | 23/58 (39.7%) | 57/58 (98.3%) |
| Event | Abiraterone |
|---|---|
| PyrexiaGeneral disorders | 4/58 |
| Back painMusculoskeletal and connective tissue disorders | 4/58 |
| Atrial fibrillationCardiac disorders | 2/58 |
| FatigueGeneral disorders | 2/58 |
| PneumoniaInfections and infestations | 2/58 |
| Haemoglobin decreasedInvestigations | 2/58 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 2/58 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/58 |
| DizzinessNervous system disorders | 2/58 |
| Spinal cord compressionNervous system disorders | 2/58 |
| Event | Abiraterone |
|---|---|
| FatigueGeneral disorders | 23/58 |
| Oedema peripheralGeneral disorders | 18/58 |
| AnaemiaBlood and lymphatic system disorders | 15/58 |
| ConstipationGastrointestinal disorders | 15/58 |
| Aspartate aminotransferase increasedInvestigations | 15/58 |
| Back painMusculoskeletal and connective tissue disorders | 15/58 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 13/58 |
| Blood albumin decreasedInvestigations | 12/58 |
| HyperglycaemiaMetabolism and nutrition disorders | 12/58 |
| NauseaGastrointestinal disorders | 11/58 |
| Age Continuous(Years) | Abiraterone |
|---|---|
| Mean | 68.6 ± 9.78 |
| Sex: Female, Male(Participants) | Abiraterone |
|---|---|
| Female | 0 |
| Male | 58 |
| Region of Enrollment(Participants) | Abiraterone |
|---|---|
| United Kingdom | 4 |
| United States | 54 |
The record gives a start of Jun 2007, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abiraterone Acetate